Six 'European' turnarounds
Although these stocks are based in Europe, they should be viewed as global powerhouses.
Many companies are considered to be European only because they are headquartered in Europe -- when in fact their operations are worldwide.
The six companies discussed below are global powerhouses with strong business franchises. As such, they are not any more vulnerable to a slowdown in Europe than are multinational companies based in the U.S. or in Asia.
Despite their global strength, their stocks have been weak in recent months as Europe’s woes make headlines almost daily. In addition to powerful brands and international reach, a number of them have very attractive dividend yields.
Sure, Europe's myriad problems are not likely to be fixed anytime soon. But the problems are well known.
Baron Rothschild is reputed to have said, "The time to buy is when there is blood in the streets." If he was right, this might be a good time to look at European stocks.
Koninklijke Philips Electronics (PHG) is the General Electric (GE) of Europe (but without GE’s big financial services business). And like GE, Philips’ stock rallied strongly into the end of the last decade, but has stagnated ever since.
Management, however, hasn’t sat still -- the company has effected significant corporate changes that have streamlined operations. While Europe is its largest market, fully two- thirds of revenues are derived outside its home turf. The latest quarter, though soft, showed some stability in operating momentum, and the stock’s valuation and dividend yield are quite attractive.
LM Ericsson Telephone (ERIC) is a global maker of telecommunications equipment. Results in recent years have been hurt by Ericsson’s joint venture with Sony in the ultra-competitive cell-phone handset market, but the company is in the process of getting out of that business. Other lines of business are doing well, with particularly good growth in South America and Asia.
The company should also see opportunities in its service operations, a fragmented market in which Ericsson is considered to be a market leader.
Novartis (NVS) was born in 1996 as a result of the merger of two Swiss drug makers, Ciba-Geigy and Sandoz. Acquisitions have continued to be a key element in the firm’s growth and diversification efforts. Though prescription drugs account for some 60% of sales, Novartis has a strong generic division as well as a presence in vaccines, diagnostics and consumer health.
A strong pipeline of new products, attractive growth metrics in emerging markets and solid operating cash flows bode well for patient investors.
Smith & Nephew (SNN) has been involved in medical technologies since 1856. Over the last decade or so the company has focused on advanced wound management, endoscopy and orthopedics. Recent operating results have been decent, but headwinds in the form of European austerity and shifting U.S. healthcare regulations have kept investors on edge.
A new CEO is expected to use acquisitions and an emphasis on emerging markets to spur long-term gains. The company’s size, worldwide-scope and solid financials bode well for continued success.
STMicroelectronics (STM) is a leader in semiconductors that help with power consumption and battery life; it is also a supplier of gyroscope chips for Apple’s iPhone. Management has shuffled the company’s assets in recent years, including exiting the memory- chip business and entering a wireless-chip joint venture with a division of Ericsson.
Although the near-term outlook is cloudy, the stock is attractively valued and the dividend pays you well in case you have to wait for a tech rebound.
Telefonica (TEF) has long been thought of as a Spanish company, but it actually has one of the more international profiles in the telecom sector with roughly two-thirds of revenues coming from outside its homeland.
Latin America is a substantial market, as are other European countries such as the UK, Ireland, Germany, Czech Republic and Slovakia. The company recently entered the Chinese market via an equity stake in China Unicom. Sales in 2010 rebounded strongly, and operations returned to profitability. The generous dividend of 8.2% appears secure.
- Sanofi-Aventis: Slid, defensive buy
- South Korea: 3 buys in a 'love to hate' market
- Global expert calls on Cellcom Israel
Copyright © 2014 Microsoft. All rights reserved.
Traders might want to bite on BABA, but long-term investors have reasons to wait.
VIDEO ON MSN MONEY
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.